Cingulate Stock price
Is Cingulate a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Cingulate Stock Analysis
Analyst Opinions
10 Analysts have issued a Cingulate forecast:
Analyst Opinions
10 Analysts have issued a Cingulate forecast:
Don't miss a Thing! We will send you all news about Cingulate directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cingulate Stock News
Company Profile
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
| Head office | United States |
| CEO | Dr. Schaffer |
| Employees | 14 |
| Founded | 2013 |
| Website | www.cingulate.com |


